首页> 外文期刊>Journal of glaucoma >Evaluation of Ex-PRESS mini glaucoma shunt implantation in refractory postpenetrating keratoplasty glaucoma.
【24h】

Evaluation of Ex-PRESS mini glaucoma shunt implantation in refractory postpenetrating keratoplasty glaucoma.

机译:Ex-PRESS微型青光眼分流植入术治疗难治性穿透性角膜移植术后青光眼的评估。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To evaluate the intraocular pressure (IOP) control and graft survival after Ex-PRESS mini glaucoma shunt implantation in refractory postpenetrating keratoplasty glaucoma. METHODS: The study included postpenetrating keratoplasty glaucoma cases unresponsive to medical antiglaucomatous therapy in whom 15 Ex-PRESS mini glaucoma shunt implantation was carried out. All glaucoma shunt implantations were performed in a separate session after penetrating keratoplasty. Nine operations were performed under general anesthesia and 6 were performed under local anesthesia. Topical antibiotherapy and topical corticosteroids were used during the postoperative first month. RESULTS: Mean age of the study population was 37.4 years (range: 10 to 80 y). IOP decreased from 41.46 mm Hg (range: 26 to 80 mm Hg) to 12.06 mm Hg (range: 8 to 25 mm Hg) over a mean follow-up of 12.2 months (range: 8 to 19 mo) (P<0.001; Wilcoxon signed rank test). IOP was below 21 mm Hg in 14 of 15 eyes (93.3%) with or without antiglaucomatous drugs. Complete success (IOP<21 mm Hg without medication) rate was 86.6%. Average number of antiglaucomatous drug usage decreased from 3.20 (range: 2 to 4) preoperatively to 0.26 postoperatively (range: 0 to 3) (P<0.001; Wilcoxon signed rank test). In 93.3% of the cases, the decrease in IOP was 30% or above postoperatively. After Ex-PRESS implantation, clear grafts remained clear while edematous grafts became clearer due to IOP decrease. Neither biomicroscopy nor pachymetry showed worsening of preoperatively opaque grafts. CONCLUSION: Ex-PRESS mini glaucoma shunt implantation may be an effective procedure for refractory postpenetrating keratoplasty glaucoma with acceptable graft failure rates in short term.
机译:目的:评估难治性穿透性角膜移植术后青光眼的Ex-PRESS迷你青光眼分流植入术后的眼压(IOP)控制和移植物存活。方法:该研究包括对药物抗青光眼治疗无反应的穿透性角膜移植术后青光眼病例,其中进行了15例Ex-PRESS微型青光眼分流植入术。穿透性角膜移植术后,所有青光眼分流术均在单独的疗程中进行。全身麻醉下进行9例手术,局部麻醉下进行6例。术后第一个月进行了局部抗生物治疗和局部皮质类固醇激素治疗。结果:研究人群的平均年龄为37.4岁(范围:10至80岁)。在平均12.2个月(范围:8到19 mo)内,IOP从41.46 mm Hg(范围:26至80 mm Hg)降低到12.06 mm Hg(范围:8至25 mm Hg)(P <0.001; Wilcoxon签署等级测试)。 15眼中有14眼的IOP低于21 mm Hg(93.3%),有或没有抗青光眼药物。完全成功率(IOP <21毫米汞柱,未服药)为86.6%。平均抗青光眼用药次数从术前的3.20(范围:2至4)降低至术后的0.26(范围:0至3)(P <0.001; Wilcoxon符号秩检验)。在93.3%的病例中,术后眼压降低为30%或以上。 Ex-PRESS植入后,由于IOP降低,透明的移植物保持透明,而水肿的移植物变得更透明。生物显微镜和测厚仪均未显示术前不透明移植物恶化。结论:Ex-PRESS微型青光眼分流术可能是治疗难治性穿透性角膜移植术后青光眼的有效方法,短期内可接受的移植失败率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号